Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$500,000.00
Jan 5, 2026
For-profit organization
MNC Collab – 34 - SC: In vivo Editing Strategy for Treatment of Sickle Cell Anemia
1039998
The MNC Collab – 34 - SC project approach requires the systemic administration of a proprietary gene editing complex. This complex will target progenitor cells within the peripheral blood and bone marrow to perform an in-vivo edit of the BCL11A enhancer, effectively reactivating the expression of fetal hemoglobin aiming at a beneficial therapeutic outcome.
$75,000.00
Oct 1, 2024
For-profit organization
ARP - MNC Collab - Immuno-Nuc-Nab - Development and Validation of CRISPR RNP delivery to Immune Cell populations
1023213
The project will focus on developing a suite of gene editing complexes capable of delivering gene edits in vivo to specific cell types. The goal is to modify, correct, or enhance cell behaviors, enabling a wide range of new therapeutic developments in key areas. This will expand treatment options and accelerate the company's growth.
$22,311.75
Jun 18, 2023
For-profit organization
Jenthera Therapeutics Inc.-2023-2024-1012164
1012164
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
$98,270.00
Dec 20, 2021
For-profit organization
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
983780
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
$13,385.00
Dec 20, 2020
For-profit organization
Innovation Assistance Program – Round 2.5
966172
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$35,632.00
Jun 25, 2020
For-profit organization
Innovation Assistance Program – Round 2
960124
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small and medium-sized enterprises that are unable to access existing COVID-19 business support.
$35,664.00
Apr 1, 2020
For-profit organization
Innovation Assistance Program
949995
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.